Ildiko Csiki, MD, PhD
Chief Medical Officer
Dr. Csiki most recently served as the chief commercial research and development (R&D) officer at City of Hope, an NCI-designated leading cancer center, where she led the development of a translational biotech-like R&D arm and oversaw the research business development and the office of transfer and licensing functions. Previously, Dr. Csiki served as the … Read more
Federica O’Brien
Consulting Chief Financial Officer
Presently Freddi is President of CFO’Brien Consulting, LLC, for which she provides executive level strategic and financial consulting services. Freddi has previously held the roles of Chief Financial Officer, Chief Operating Officer, Controller and Director of Financial Reporting and has been integral in the growth and financing of both private and public companies ranging from … Read more
Jian Yan, PhD
Vice President, Research and Discovery
Dr. Yan joined Geneos to lead the research team and brings with her over 15 years of experience in leading preclinical research programs for the development of novel immunotherapies. Prior to joining Geneos, she served as the Vice President of Design and Product Development at NEUVOGEN, where she was responsible for design and development of … Read more
Shawn Tomasello, MBA
Advisor
Shawn Cline Tomasello joined Kite Pharma in 2015 as Chief Commercial Officer (CCO) with over 30 years of experience in pharmaceutical and biotech industries. She was a key executive in the Kite/Gilead acquisition for $11.9 Billion in August 2017. Prior to joining Kite Pharma, Ms. Tomasello was the CCO of Commercial and Medical Affairs at … Read more
Myrna Thomas
Vice President, Quality and Manufacturing
Myrna Thomas serves as Vice President, Quality – Manufacturing at Geneos Therapeutics, overseeing quality operations to ensure compliance with global regulatory standards and supporting the advancement of the company’s personalized immunotherapy oncology platform. She brings over 20 years of biopharmaceutical experience, with expertise in GMP manufacturing, quality systems, and regulatory compliance. Ms. Thomas has held … Read more
Chi Van Dang, MD, PhD
Scientific Director, Ludwig Institute for Cancer Research; Bloomberg Distinguished Professor of Cancer Medicine, Johns Hopkins University
Dr. Chi Van Dang is scientific director of the Ludwig Institute for Cancer Research and Bloomberg Distinguished Professor of Cancer Medicine at Johns Hopkins University. He is also Professor of Oncology, Cell Biology, and Biochemistry and Molecular Biology at Johns Hopkins. Dang’s research helped define the complex functions of the MYC oncogene, a central switch … Read more
David B. Weiner, PhD
W.W. Smith Endowed Chair in Cancer Research, The Wistar Institute
Dr. David Weiner directs a translational research laboratory at The Wistar Institute in the area of Molecular Immunology. His group is one of the pioneering research teams in establishing the field of DNA vaccines and immunotherapies. Important reports from his lab include the first DNA vaccine studied for HIV as well as for cancer immunotherapy, … Read more
Omar H. Khalil
Partner, Sante Ventures
Omar H. Khalil manages Santé’s Boston Office and concentrates on biotechnology, where he partners with scientific founders and entrepreneurs across multiple therapeutic areas and modalities. Omar joined Santé in 2007 and rejoined in 2020 after holding various transactional and operational leadership roles within the pharmaceutical and biotech industry. He held senior leadership roles with Baxter International, … Read more
James Eadie, MD
Partner, Santé Ventures
James Eadie, MD received his MD from Harvard Medical School, an MBA from the University of Texas McCombs School Of Business, and a BS in bioengineering, Summa Cum Laude, from the University of Michigan. He is board certified in emergency medicine and completed his residency at Massachusetts General Hospital and Brigham and Women’s Hospital. Previously, … Read more
Sangwoo Lee
Managing Director — Korea Investment Partners US Inc.
Mr. Lee is Head of Korea Investment Partners (KIP’s) US office based in Silicon Valley and actively explores cross-border investments to contribute to the global expansion of Korea Investment Partners. He is currently managing over 12 companies in his investment portfolio and participates actively on more than 7 boards. Portfolio companies range from biotech/healthcare companies … Read more